Effect of Vitamin D Supplements on Relapse of Digestive Tract Cancer with Tumor Stromal Immune Response: A Secondary Analysis of the AMATERASU Randomized Clinical Trial
Open Access
Abstract
The aim was to examine whether vitamin D supplementation (2000 IU/day) reduces the risk of relapse in a subgroup of patients with digestive tract cancer, showing a sufficient immune response in tumor stroma by conducting secondary subgroup analyses of the AMATERASU randomized, double-blind, placebo-controlled trial (UMIN000001977). A total of 372 patients were divided into two subgroups stratified by the median density of immune cells infiltrating in tumor stroma into higher and lower halves. In the higher-half subgroup of CD56+ cells, the relapse ratio was significantly lower in the vitamin D group (7.4%) than in the placebo group (20.5%) (subdistribution hazard ratio (SHR), 0.35; 95% confidence interval (CI), 0.15–0.82), but it was equivalent (25.2% vs. 22.7%) in the lower-half subgroup of CD56+ cells (SHR, 1.21; 95% CI, 0.68–2.19) with a significant interaction (Pinteraction = 0.02). Although there were no significant differences, the risk of relapse was lower in the vitamin D group than in the placebo group in the higher half of CD45RO+ memory T cells (8.9% vs. 19.2%), and of CD8+ cytotoxic T cells (11.3% vs. 22.5%). In patients with digestive tract cancer, vitamin D supplementation was hypothesized to reduce the risk of relapse in the subgroup of patients who already have an adequate infiltration of immune cells in their tumor stroma.Keywords
Funding Information
- Japan Society for the Promotion of Science (20H03537)
This publication has 32 references indexed in Scilit:
- Vitamin D and Immune FunctionNutrients, 2013
- Ki‐67 labeling: A more sensitive indicator of malignant phenotype than mitotic count or tumor size?Journal of Surgical Oncology, 2012
- The immune contexture in human tumours: impact on clinical outcomeNature Reviews Cancer, 2012
- Tumor-Infiltrating CD8+Lymphocytes Predict Clinical Outcome in Breast CancerJournal of Clinical Oncology, 2011
- The clinical utility of Ki‐67 in assessing tumor biology and aggressiveness in patients with appendiceal carcinoidsJournal of Surgical Oncology, 2010
- Lymphocytic Reaction to Colorectal Cancer Is Associated with Longer Survival, Independent of Lymph Node Count, Microsatellite Instability, and CpG Island Methylator PhenotypeClinical Cancer Research, 2009
- Prospects for the use of NK cells in immunotherapy of human cancerNature Reviews Immunology, 2007
- Effector Memory T Cells, Early Metastasis, and Survival in Colorectal CancerNew England Journal of Medicine, 2005
- Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian CancerNew England Journal of Medicine, 2003
- A Proportional Hazards Model for the Subdistribution of a Competing RiskJournal of the American Statistical Association, 1999